## Heather Wakelee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12184945/publications.pdf

Version: 2024-02-01

26 papers

3,173 citations

430874 18 h-index 25 g-index

26 all docs

26 docs citations

times ranked

26

4760 citing authors

#	Article	IF	CITATIONS
1	Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet, The, 2021, 398, 1344-1357.	13.7	689
2	COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncology, The, 2020, 21, 914-922.	10.7	503
3	Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ⟨i>ALK⟨ i>-Rearranged Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. Journal of Clinical Oncology, 2016, 34, 2866-2873.	1.6	316
4	Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative) Tj ETQq0 0 0 0	rgBT /Over 13.7	lock 10 Tf 50
5	A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma. Journal of Thoracic Oncology, 2016, 11, 1690-1700.	1.1	256
6	Assessment of <i>EGFR</i> Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686). Clinical Cancer Research, 2016, 22, 2386-2395.	7.0	169
7	Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 165-183.	1.1	134
8	Role of Anti-angiogenesis Agents in Treating NSCLC: Focus on Bevacizumab and VEGFR Tyrosine Kinase Inhibitors. Current Treatment Options in Oncology, 2007, 8, 15-27.	3.0	115
9	Development of the International Thymic Malignancy Interest Group International Database: An Unprecedented Resource for the Study of a Rare Group of Tumors. Journal of Thoracic Oncology, 2014, 9, 1573-1578.	1.1	106
10	Clinicopathologic Features of Advanced Squamous NSCLC. Journal of Thoracic Oncology, 2016, 11, 1411-1422.	1.1	101
11	Lung Cancer Among Postmenopausal Women Treated With Estrogen Alone in the Women's Health Initiative Randomized Trial. Journal of the National Cancer Institute, 2010, 102, 1413-1421.	6.3	100
12	Optimizing First-Line Treatment Options for Patients with Advanced NSCLC. Oncologist, 2005, 10, 1-10.	3.7	77
13	Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non–Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 274-281.	7.0	75
14	Determinants of Complete Resection of Thymoma by Minimally Invasive and Open Thymectomy: Analysis of an International Registry. Journal of Thoracic Oncology, 2017, 12, 129-136.	1.1	62
15	TERAVOLT: Thoracic Cancers International COVID-19 Collaboration. Cancer Cell, 2020, 37, 742-745.	16.8	51
16	Hormone Use, Reproductive History, and Risk of Lung Cancer: The Women's Health Initiative Studies. Journal of Thoracic Oncology, 2015, 10, 1004-1013.	1.1	44
17	Estrogen Plus Progestin and Lung Cancer: Follow-up of the Women's Health Initiative Randomized Trial. Clinical Lung Cancer, 2016, 17, 10-17.e1.	2.6	30
18	Calcium plus vitamin D supplementation and lung cancer incidence among postmenopausal women in the Women's Health Initiative. Lung Cancer, 2017, 110, 42-47.	2.0	23

#	Article	IF	CITATIONS
19	Antiangiogenic Agents and Vascular Disrupting Agents for the Treatment of Lung Cancer: A Review. Journal of Thoracic Oncology, 2010, 5, 129-139.	1.1	13
20	A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry. Journal of Thoracic Oncology, 2022, 17, 661-674.	1,1	9
21	Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis. JTO Clinical and Research Reports, 2022, 3, 100335.	1.1	7
22	Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience. Cancer Cell, 2020, 38, 602-604.	16.8	6
23	Overcoming Resistance Without the Risk of Reaction: Use of Afatinib and Panitumumab in Two Cases of Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer With T790M Mutations. Clinical Lung Cancer, 2015, 16, e97-e99.	2.6	3
24	Lung cancer and hormone replacement therapy – Authors' reply. Lancet, The, 2010, 375, 118-119.	13.7	1
25	Adjuvant therapy for early-stage non–small cell lung cancer: The breaking of a new dawn. Journal of Thoracic and Cardiovascular Surgery, 2022, , .	0.8	1
26	Does plasma-based molecular testing have a role in the routine care of lung cancer?. Clinical Advances in Hematology and Oncology, 2017, 15, 599-601.	0.3	0